TW201630596A - Sphingolipid absorption promoter - Google Patents

Abstract

A sphingolipid absorption promoter that comprises as an active ingredient a fermentation product and/or a culture product of a lactic acid bacterium and/or a bifidobacterium. According to the present invention, when a sphingolipid is taken, the absorption of the sphingolipid can be improved or promoted and thus the sphingolipid can be safely easily and economically (or efficiently) absorbed.

Description

Sheath lipid absorption enhancer [Related application reference]

The present application is based on Japanese Patent Application No. 2015-000745 (filed on Jan. 6, 2015), the entire disclosure of which is hereby incorporated by reference. .

The present invention relates to Absorption Promoter of Sphingolipid. Further, the present invention relates to a composition for oral ingestion or enteral administration comprising a lactic acid bacterium and/or a fermented product and/or culture of a bacterium of the bacterium, and an additional sphingolipid.

The sphingolipid is a component of the cell membrane of eukaryotes, and is a general term for a sphingoid base. It has been found that the effect of improving the barrier function based on oral ingestion of the skin.

Sphingomyelin is derived from one of the sheath lipids of milk. Regarding sphingomyelin, it has been known that the skin condition is deteriorated (the skin barrier function is lowered, the skin is dry, the skin is rough, the water in the stratum corneum is lowered, the atopic dermatitis, etc.) is prevented or improved.

Further, regarding sphingomyelin, cancer (colorectal cancer) suppression is known. System function (Sugawara Tatsuya, "Digestion and absorption of sphingolipids as a functional component of food", Japanese Nutrition, Food and Food Society, Vol. 66, No. 4, pp. 177-183 (2013)), and skin function (Japanese special) 2008-184428), the development of the brain development of infants and young children (Japanese Patent No. 3203485), the function of improving the function of the mitochondria (Japanese Unexamined Patent Publication No. 2011-157329), and the improvement of the exercise function (Japanese Patent Laid-Open No. 2014-141496) Bulletin), visceral fat accumulation inhibition, and promotion of blood lipid concentration increase (antihyperglycemic action, antihyperlipidemic effect) (JP-A-2007-320900), infection prevention effect (JP-2008) Bulletin No. 037788).

Sphingomyelin is a substance composed of neuropterin and choline, which is hydrolyzed by sphingomyelinase to neuropterin and choline. Further, the neuropterin is hydrolyzed into a sphingoid base and a fatty acid by a neural guanamine, and most of it is absorbed as a fatty acid by the epithelial cells of the small intestine, and a part of the sphingoid base is recombined into a sphingomyelin or a neurosteroid. Further, it has been suggested that sphingomyelin is decomposed by intestinal bacteria.

Glycoside is a substance in which glucose is bound to a nervous amine formed from a sphingoid base and a fatty acid. Hydrolysis to ceramide and glucose by glycosylamine catalyzed enzymes. The galactose neural amide galactose is a substance obtained by binding to a ceramide and a ceramide.

Generally, when the lipid is orally ingested, it is emulsified by bile acid, decomposed into a fatty acid and a monoglyceride by a lipase, and absorbed by the small intestine. Further, the monoglyceride is synthesized in the epithelial cells of the small intestine and then synthesized into three The glyceride is a chylomicron that is transported to the lymphatic vessels and passes through the chest tube and circulates toward the whole body.

However, the digestion of sphingomyelin or ceramide has been clarified. Low absorption. The reason for this is considered to be because the activity of the sphingomyelinase in the digestive tract is low, or the transporter represented by it, and the sphingoid base which is temporarily absorbed is discharged.

Therefore, when the sheath lipid containing sphingomyelin which is expected to have various actions as described above is orally ingested, it is desired to improve the absorbability of the sphingolipid, and it is safe, simple, and effective.

Regarding the improvement of the digestion and absorption of lipids, for example, in Japanese Patent No. 3920969, there is proposed a nutritional composition in which a bile acid or a bile acid salt is formulated in order to enhance digestion and absorption of lipids. However, sphingolipids are not described therein, and bile acids themselves are bitter, and their effects must be considered when used as foods.

Fermented milk (Yug) is a fermented food prepared by fermenting lactic acid bacteria or yeast in milk, and is widely consumed because it is delicious and based on beauty and healthy noodles.

For example, Japanese Laid-Open Patent Publication No. Hei 7-327633 discloses chitosan processed foods in which chitosan, glutinous rice, and yogurt are mixed. Here, the yoghurt powder has a function of contributing to the digestion and absorption of chitosan. However, the digestive absorption function here focuses on the action of active lecithin in the yogurt powder, which does not reveal or suggest the promotion of digestion and absorption of the sheath lipid.

The present inventors have now unexpectedly discovered that if the fermented milk (Yug) is taken together with the sphingolipid, the absorption amount of the sphingolipid to the living body can be increased, and the absorption of the sphingolipid can be improved. At this time, the present inventors have also found that the absorption of neuropterin can be improved. In addition, the present inventors have found that the absorption of sphingolipids can be promoted by ingesting lactic acid bacteria and/or fermented products and/or cultures of P. vivata. Further, by increasing the absorption amount of the sphingomyelin-containing sphingolipid to the living body, it is possible to achieve an improvement in the skin barrier function and various beneficial effects or effects associated with the absorption of the sheath lipid. Therefore, the inventors of the present invention have actually confirmed that the absorption amount of sphingomyelin in the living body can be improved by preparing an oral or enteral composition containing sphingomyelin having a superiority and a superior content. The present invention has been completed based on these and the like.

Accordingly, it is an object of the present invention to provide means for enhancing or promoting the absorption of sphingolipids when ingesting sphingolipids, and which is safe, simple, and economical (or effective).

That is, the following invention is provided in accordance with the present invention.

<1> A sphingolipid absorption enhancer which comprises a lactic acid bacterium and/or a fermented product and/or culture of a bacterium of the bacterium, as an active ingredient.

<2> The sheath lipid absorption enhancer according to the above <1>, wherein the sphingolipid is a sphingomyelin and promotes absorption of sphingomyelin into the living body.

<3> The sheath lipid absorption enhancer according to the above <2>, which promotes absorption of the sphingomyelin derived from milk into the living body.

The sheath lipid absorption enhancer according to any one of the above aspects, wherein the sphingolipid is a neurosteroid, a glucosylceramide, or a galactose neural amide.

The sphingolipid absorption enhancer according to any one of the above-mentioned <1> to <4>, wherein the lactic acid bacterium and/or the fermented product and/or the culture of the bacterium of the bacterium, lactic acid bacteria and/or bacterium Milk ferment and/or milk culture.

<6> A sheath lipid absorption enhancer which uses a polysaccharide as an active ingredient.

<7> A composition for oral ingestion or enteral administration comprising the sheath lipid absorption enhancer according to any one of the above <1> to <6> and a sphingolipid.

<8> A composition for oral ingestion or enteral administration comprising a lactic acid bacterium and/or a fermented product and/or a culture of the bacterium, and an additional sphingolipid.

<9> The composition for oral ingestion or enteral administration according to the above <7> or <8>, wherein the ratio of the fermentation product and/or the culture of the lactic acid bacteria and/or the bacterium, and the culture to the sphingolipid is It contains 1 to 10000 mg of lactic acid bacteria and/or fermented products and/or cultures of P. fluorescens (dry weight (powder)) with respect to 1 mg of sphingolipid.

<10> The oral ingestion or enteral administration composition according to the above <7> or <8>, wherein the ratio of the fermentation product and/or the culture of the lactic acid bacteria and/or the bacterium of the bacterium to the sphingolipid is It contains 0.01 to 100 g of a lactic acid bacterium and/or a fermented product and/or a culture (wet weight) of the bacterium of the genus Helicobacter relative to 1 mg of the sphingolipid.

The composition for oral ingestion or enteral administration according to any one of the above items <7> to <10>, wherein the sphingolipid sphingomyelin.

<12> Oral ingestion according to any one of the above <7> to <11> Or a composition for enteral administration, which is used for the action in the body induced by absorption of sphingomyelin into the living body.

<13> The composition for oral ingestion or enteral administration according to the above <12>, wherein the action in the living body of the above <7> is for preventing or improving the deterioration of the skin condition, the cancer suppressing action, the skin function, and the infant. A group of children who have developed brain development, mitochondrial function, exercise function, visceral fat accumulation inhibition, and blood lipid concentration increase promotion and infection prevention.

The composition for oral ingestion or enteral administration according to any one of the above items <7> to <11>, which is for preventing, suppressing or improving the deterioration of the skin condition.

<15> The composition according to the above <14>, wherein the deterioration of the skin condition is deterioration of the skin barrier function.

The composition of the above-mentioned <1> to <6>, or the composition of any one of <7> to <15>.

<17> The food or drink according to the above <16>, which is a functional food, a healthy nutritious food, a supplement, a specific health food, a functional food, or a food having a reduced risk of disease.

<18> A method for promoting absorption of sphingolipids, which comprises simultaneously administering a lactic acid bacterium and/or a fermented product and/or culture of lactic acid bacteria to a subject desirably taking sphingolipids and a sphingolipid.

<19> The absorption promoting method according to the above <18>, wherein the sphingolipid sphingomyelin.

According to the sheath lipid absorption enhancer of the present invention, when sphingomyelin is ingested, the absorption of sphingomyelin can be enhanced or promoted, and further, sphingomyelin can be absorbed safely, simply, economically (or effectively). Since the yoghurt used in the absorption enhancer and the composition of the present invention has experience in the past as a food, it has high safety, is simple in actual intake, and is economically advantageous.

Fig. 1 is a graph showing the result of Example 1 (transition (cumulative value) of the amount of neuropterin molecules in the lymph fluid).

Fig. 2 is a graph showing the result of Example 1 (the transition (cumulative value) of the amount of sphingomyelin molecules in the lymph fluid).

Fig. 3 is a graph showing the results of Example 2 (changes in the amount of neuropterin molecules in serum) (in the figure, * means meaningful difference (P < 0.05) for the MPL group).

Fig. 4 is a graph showing the results of Example 2 (area under the time curve of the amount of neuropterin molecules in serum) (in the figure, * means meaningful difference (P < 0.05) for the MPL group).

Fig. 5 is a graph showing the transition of the water content of the stratum corneum in the test 1 of Example 3 (significant difference (P < 0.05) between different English numerals).

Figure 6 is a graph showing the percutaneous moisture evaporation in the test 1 of Example 3. Shift chart (with significant difference between different English numbers (P<0.05)).

Figure 7 is a graph showing the results of Example 4 (area under the time curve of the amount of neuropterin molecules in serum) (in the figure, * means meaningful difference for the MPL group (P < 0.05), # meaning for the The fermented milk group had a meaningful difference (P < 0.05)).

Fig. 8 is a graph showing the results of Example 5 (area under the time curve of the amount of neuropterin molecules in serum) (in the figure, * means meaningful difference (P < 0.05) for the MPL group).

Fig. 9 is a graph showing the results of Example 6 (area under the time curve of the amount of neuropterin molecules in serum) (in the figure, * means meaningful difference (P < 0.05) for the MPL group).

Fig. 10 is a graph showing the results of Example 7 (area under the time curve of the amount of neuropterin molecules in serum) (in the figure, * means meaningful difference (P < 0.05) for the MPL group).

Fig. 11 is a graph showing the results of Example 8 (area under the time curve of the amount of neuropterin molecules in serum) (in the figure, * means meaningful difference (P < 0.05) for the MPL group).

Fig. 12 is a graph showing the results of Example 9 (area under the time curve of the amount of neuropterin molecules in serum) (in the figure, * means meaningful difference (P < 0.05) for the MPL group).

Fig. 13 is a graph showing the results of Example 10 (area under the time curve of the amount of neuropterin molecules in serum) (in the figure, * means meaningful difference (P < 0.05) for the MPL group).

Hereinafter, embodiments of the present invention will be described.

Sheath lipid absorption enhancer

The sheath lipid absorption enhancer of the present invention is as described above, and the fermented product and/or the culture of the lactic acid bacteria and/or the bacterium of the bacterium is an active ingredient. The term "acting as an active ingredient" as used herein means a fermentation of a lactic acid bacterium and/or a bacterium of the genus Fischerella which can sufficiently exert (i.e., be effective) the action of the absorption enhancer of the present invention to promote the absorption of sphingolipids in the living body. And/or culture.

Further, the term "absorption promotion" of the sheath lipid herein means promoting the absorption of the sheath lipid into the living body. Therefore, the term "absorption" as used herein generally means that the sheath lipid which is orally or sequentially administered by the absorption enhancer of the present invention or the sheath lipid which has been taken up in the body passes through the digestive tract or the absorption channel or the like. The body membrane is ingested into a circulatory organ (vascular system or lymphoid system) or the like in the living body, whereby the actually absorbed sphingolipid can exert various effects on the living body as a sphingolipid or a derivative thereof.

Here, "promoting" means that the absorption of the sheath lipid is more promoted than when the absorption enhancer is not used. Here, if the absorption amount is increased, the absorption rate is increased, and the reduced absorption energy and the like are improved. Further, in the preferred embodiment of the present invention, "promoting" is used in the sense of increasing the absorption amount of the sheath lipid in the living body.

In the present specification, the sheath lipid is derived from a natural one, and is exemplified by, for example, milk derived from cow's milk, goat's milk, goat's milk, horse milk, etc., derived from egg yolk, derived from soybean, rice, corn, grain, and derived from Capricorn, derived from beets Etc., preferably from the milk, better from the milk. The sphingolipid contains sphingomyelin, glucosylceramide, galactose neural amide. The sphingolipid is preferably a sheath lipid, more preferably a sphingomyelin. These may also be prepared by a conventional method using a natural raw material, or a commercially available product may be used.

In the present invention, the sphingomyelin which can be used is one of sphingolipids, and similarly to the sphingolipid as described above, it is derived from a natural one, preferably from a milk, and more preferably from a cow's milk. Sphingomyelin can also be prepared from natural materials by conventional methods, and commercially available products can also be used.

According to a preferred aspect of the invention, the sphingolipid absorption enhancer promotes absorption of the sphingomyelin derived from milk into the living body.

In the present invention, the absorption of a sphingolipid (e.g., sphingomyelin) can be evaluated by measuring the quality of the sphingolipid in the living body. At this time, for example, focusing on a certain molecular species of sphingomyelin, the absorption of sphingomyelin can also be evaluated by measuring the amount of the molecular species taken into the living body. Alternatively, the absorption of sphingomyelin can also be evaluated by measuring the amount of sphingomyelin derivative, for example, the amount of neuropterin produced by hydrolysis of sphingomyelin in the living body.

The sphingomyelin, especially the molecular species contained in the sphingomyelin derived from milk, can be exemplified as follows: That is, the sphingosine or dihydroxysphingosine having a carbon chain number of 16 to 18 and the fatty acid having a carbon chain of 14 to 26 each having a guanamine-bonded neuropterin structure are bonded with phosphorylcholine or phosphonium ethanolamine. The sphingomyelin molecular species.

The absorption of sphingomyelin is evaluated by considering the amount of one of these molecular species or a combination thereof, and measuring the amount thereof or the amount of its derivative substance.

As described above, sphingomyelin is a substance composed of ceramide and choline, which is hydrolyzed by sphingomyelinase into neuropterin and choline. The neuropterin is in turn hydrolyzed to a sphingoid base and a fatty acid by a neural guanamine. Therefore, in addition to promoting the absorption of sphingomyelin, the sphingolipid absorption enhancer also promotes the absorption of neuropterin into the living body.

Therefore, the sphingolipid absorption enhancer according to the present invention also promotes the absorption of neuropterin into the living body.

According to another aspect of the present invention, absorption of a nervous amide, a saccharide ceramide, and/or a galactose ceramide by using a lactic acid bacterium and/or a fermented product and/or a culture of the bacterium of the bacterium Promoter. According to the absorption enhancer of the neuropterin, glucosylceramide and/or galactose ceramide of the present invention, it also promotes neuropterin, glucosylceramide, galactose-neuraminide or the like The combination of the above combinations is absorbed into the living body.

In the present invention, examples of the molecular species contained in the neuroketamine, the glucosylceramide, and the galactosylceramide may be, for example, the following.

That is, sphingosine, dihydroxysphingosine, sphingadienine, phytosphingosine or hydroxysphingenine with carbon chain number 16~18 and carbon chain 14~26 The fatty acid or hydroxy fatty acid is each amidoxime-bonded neuropterin molecular species. The above-mentioned neuropterin molecule is a species of glucosamine ceramide which is linked to glucose. The above-mentioned neuroketamine molecule is a kind of galactose neural amide molecule which is linked to galactose.

In the present invention, the so-called "lactic acid bacteria and / or the bacteria than the bacteria" The fermentation product and/or the culture includes a fermentation product of lactic acid bacteria and phenanthrene bacteria, a fermentation product of lactic acid bacteria, a fermented product of phenanthrene bacteria, a culture of lactic acid bacteria and phenanthrene bacteria, a culture of lactic acid bacteria, and a phenanthrene. The culture of the bacterium and the meaning of the combination are used.

In the present invention, the "lactic acid bacteria" is a general term for microorganisms which synthesize glucose and produce lactic acid having a sugar yield of 50% or more, and is a bacterium having a physiological property of a gram-positive bacterium or a bacterium, and has no motility or spore formation. Capable of having the characteristics of negative catalytic enzymes, etc. The lactic acid bacteria system has been eaten all over the world through fermented milk since ancient times, and it is a highly safe microorganism. Lactic acid bacteria have heretofore been classified into Lactococcus, Lactobacillus, Leuconostoc, Pediococcus, Streptococcus, Wissella, and IV. It is a genus of the genus Tetragenococcus, Oenococcus, Enterococcus, Vagococcus, and Carnobacterium. In the present invention, these lactic acid bacteria can be used. Among these, as preferred lactic acid bacteria, for example, Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, Lactobacillus lactis, Lactobacillus gasseri ( Lactobacillus gasseri) and so on. It is especially preferred to use a mixed starting material of Lactobacillus bulgaricus and Streptococcus thermophilus.

In the present invention, the "Bienia species" is a microorganism which synthesizes glucose and produces acetic acid or lactic acid, and belongs to the genus Bifidobacterium. (Bifidobacterium) is a microorganism. For example, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium breve, and the like can be exemplified.

According to a preferred embodiment of the present invention, the lactic acid bacteria system comprises a combination of Lactobacillus bulgaricus and Streptococcus thermophilus, more preferably a combination of Lactobacillus bulgaricus and Streptococcus thermophilus.

In addition, the "fermented product" in the present invention means a culture itself obtained by fermentation with lactic acid bacteria and/or bacteria. The "fermentation product" in the present invention includes a lactic acid bacterium and/or a fermented product of the bacterium, and a treated product thereof, for example, the culture (lactic acid bacteria and/or fermented bacteria) is filtered. The culture filtrate obtained by centrifugation or sterilization by membrane separation or the culture supernatant, the aforementioned culture filtrate. A concentrate, a paste, a dilution, or a dried product (freezing, heating, decompression, or the like) concentrated by an evaporator or the like, such as a supernatant or a lactic acid bacterium and/or a fermented product such as a bacterium of the bacterium.

Further, in the present invention, in the production of the treated material, one type or a combination of the above-mentioned processing steps such as filtration, centrifugation, membrane separation, and the like may be combined, and the mixture may be used in combination or in combination. .

Further, the medium of the "culture" in the present invention is exemplified by, for example, a skim milk powder medium to which yeast enzyme is added, an MRS medium, or the like.

According to a preferred embodiment of the present invention, "the lactic acid bacteria and/or the fermented product and/or culture of the bacterium bacterium" is a milk fermentation product and/or a milk culture of lactic acid bacteria and/or bacterium. Further, according to a preferred aspect of the present invention, "a lactic acid bacterium and/or a fermented product and/or a culture of the bacterium bacterium" is issued. Yeast milk (Yug). Here, the aforementioned superiority is called its supernatant. According to a preferred aspect of the present invention, "a lactic acid bacterium and/or a fermented product and/or a culture of the bacterium bacterium" is a polysaccharide. Here, the polysaccharide is preferably derived from a fermented product and/or a culture.

Therefore, according to another aspect of the present invention, a sheath lipid absorption enhancer comprising a polysaccharide as an active ingredient is provided.

In the present invention, the "milk fermented product and/or milk culture", that is, the "fermented product of milk and/or milk" means that the raw material containing milk is fermented or cultured. Examples of the milk are animal milk such as cow's milk or processed products thereof (for example, skim milk, whole milk powder, skim milk powder, condensed milk, casein, whey, raw milk fat, mixed cream, cream, cream powder, etc.) or A vegetable milk derived from soybean milk or the like.

The raw material of the fermented milk is exemplified by, for example, a cow's milk which is called fermented milk.

The fermented milk raw milk comprises a mixture of raw milk and other ingredients, for example, by using raw milk, water, and other optional ingredients (such as sugar, sugar, sweetener, sour, minerals, vitamins, spices, etc.) The raw materials commonly used in the manufacture of fermented milk are obtained by heating and dissolving and mixing. Further, the fermented milk may be used as a tackifier or a gelling agent for pectin, guar gum, tragacanth gum, carrageenan, processed starch or the like in a culture liquid such as skim milk powder or whey protein decomposition product. The milk contains the former and the latter. The specific raw materials (materials) of the raw milk may also include water, raw milk, sterilized milk, skim milk, whole milk powder, skimmed milk powder, whole fat concentrated milk, skim milk concentrate, buttermilk, cream, milk fat and the like. Also, it contains whey protein concentrate (WPC) and whey eggs. White matter isolate (WPI), α-lactalbumin (α-La), β-lactoglobulin (β-Lg), and the like.

The method for producing fermented milk includes a mixing step of mixing (blending) the raw material milk of the raw material. In the mixing step of the raw material milk, the usual conditions used in the production of the fermented milk may be appropriately employed. Further, the method for producing the fermented milk of the present invention includes the (heating) sterilization step of the raw material milk, the cooling step of the raw material milk, the starting material addition step, the fermentation step, and the cooling step of the fermented milk, as in the conventional method. The order is included. Further, in these steps, the usual conditions used in the production of the fermented milk may be appropriately employed.

As the medium for culturing lactic acid bacteria or the like, a medium which is usually used can be used. In other words, any medium may be used as long as it contains a nitrogen source or a nutrient other than the main carbon source. As the carbon source, lactose, glucose, sucrose, fructose, starch hydrolyzate, waste honey or the like can be used depending on the metabolic synthesis of the bacteria to be used. As the nitrogen source, an organic nitrogen-containing substance such as a hydrolyzate of casein, a whey protein hydrolyzate, α-lactalbumin, β-lactoglobulin, a glycopolypeptide, or a soy protein hydrolyzate can be used. Further, as the growth promoter, a meat extract, a fish extract, a yeast extract or the like can be used.

The condition for culturing the lactic acid bacteria or the like is preferably an anaerobic state, but it is also possible to use a microaerobic state such as a liquid static culture which is usually used. The culture in the anaerobic state can be applied to a conventional method such as a method of culturing under a carbon gas layer, but other methods are also possible. The culture temperature is generally preferably from 30 to 47 ° C, more preferably from 35 to 46 ° C, and even more preferably from 37 to 45 ° C. The pH of the lactic acid bacteria is equal to the pH of the medium in the culture, but the temperature can be maintained at 6~7. It can also be other pH conditions. The incubation time of the lactic acid bacteria or the like is usually preferably from 1 to 48 hours, more preferably from 8 to 36 hours, and even more preferably from 10 to 24 hours.

A typical example of the fermented milk (Yug) in the present invention is a fat-free milk solid content of 8% by weight or more, and a lactic acid bacteria number or a yeast number of 10 million/ml or more. For example, 10 ¹¹ /ml or more.

use

The lactic acid bacterium of the active ingredient of the present invention and/or the fermented product and/or culture of the bacterium of the bacterium having a sphingolipid absorption promoting activity (Examples 1 and 2 to be described later) usually have an absorption promoting activity of neural guanamine. Therefore, by using the sphingolipid absorption enhancer of the present invention, the absorption of the sphingolipid in the living body can be enhanced, so that various effects exerted by the presence of the sphingolipid or a derivative thereof in the living body can be further enhanced. This is of course the same when the sphingolipid is sphingomyelin. By using the sphingomyelin absorption enhancer of the present invention, the absorption of sphingomyelin in the living body can be improved, so that the sphingomyelin or its derivative in the living body can be further improved. The various roles played by the existence of matter.

Further, in the same manner, when the sphingolipid is a neurosteroid, a glucosamine or a galactose, the absorption enhancer of the ceramide, the glucosamine or the galactosamine is used. It can increase the absorption of neuropterin, glucosylamine or galactose neural amine in the body. Therefore, it is possible to further enhance various effects exerted by the presence of the neurosteroids, glucosylamines or galactosylceramides in the living body and the presence of such derivatives.

By increasing the presence of sphingomyelin or its derivatives in the body In the amount, the skin condition is deteriorated (the skin barrier function is lowered, the skin is dry, rough, the moisture content of the stratum corneum is lowered, atopic dermatitis, etc.) is improved, improved, enhanced, and prevented.

In addition, by increasing the amount of sphingomyelin or its derivative in the body, it exerts a cancer (colorectal cancer) inhibitory action. (Sugawara Tatsuya, "Digestion and absorption of sphingolipids as a functional ingredient of food", Japanese nutrition.志志, Vol. 66, No. 4, pp. 177-183 (2013)), the role of the skin (Japanese Unexamined Patent No. 2008-184428), the promotion of brain development in infants and young children (Japanese Patent No. 3203485), the function of the mitochondria Enhancement (JP-A-2011-157329), exercise function improvement (JP-A-2014-141496), inhibition of visceral fat accumulation, and promotion of blood lipid concentration increase (antihyperglycemic effect, high fat resistance) (Blood effect) (Japanese Patent Laid-Open Publication No. 2007-320900), and a preventive action for infectious diseases (JP-A-2008-037788).

Therefore, these effects can be obtained by promoting the absorption of the sheath lipid by the sheath lipid absorption enhancer of the present invention.

Further, as shown in the third embodiment to be described later, the skin barrier function can be further improved in the state in which the skin barrier function due to ultraviolet rays is lowered by the absorption of the sphingolipid.

In the present invention, the deterioration of the skin condition includes, for example, a reduction in the barrier function of the skin, a dry skin, a rough skin, a decrease in the moisture content of the stratum corneum, atopic dermatitis, and the like. The reduction of the skin barrier function also includes the maintenance of the barrier function. Moreover, the reduction of the barrier function of the skin is preferably a reduction in the skin barrier function under ultraviolet irradiation.

Here, the "prevention, suppression, or improvement" of the deterioration state is used in the sense of including the adjustment of these states, delaying, alleviating, preventing the onset, preventing recurrence, and the like.

Therefore, according to the present invention, since the sphingolipid which is absorbed in the living body can be increased by the absorption of the sphingolipid, the effect (function, efficacy) in the living body induced by the absorption of the sphingolipid in the living body can be achieved. Improve, enhance. Moreover, the action in the living body here is induced by absorption of the sheath lipid in the living body, and as described above, various effects can be improved. Therefore, according to the present invention, an enhancer (function enhancer accompanying sheath lipid absorption (ingestion)) which is induced by the absorption of the sheath lipid can also be provided.

Oral ingestion or enteral administration

As described above, according to the present invention, there is provided an orally ingestible or enteral administration composition comprising the active ingredient of the present invention, that is, a fermentation product and/or a culture of a lactic acid bacterium and/or a bacterium of the bacterium, and a sphingolipid. The composition may also contain the sheath lipid absorption enhancer of the present invention as such an active ingredient.

The lactic acid bacteria and/or the fermented product and/or culture of the bacterium of the bacterium, in many cases, itself contain both sphingolipids, but in a preferred aspect of the invention, the composition of the present invention comprises lactic acid bacteria and/or phenanthrene. Fermentation and/or culture of the bacteria and additional sheath lipids. Therefore, the composition of the present invention is distinguished from the lactic acid bacteria and/or the fermented product and/or culture of the conventional yoghurt.

Here, the term "additional sphingolipid" is used in lactic acid bacteria and/or Bifido When the fermentation product and/or the culture contains the sphingolipid, it means that it is added to the composition in excess of the amount of the lactic acid bacterium and/or the sphingolipid itself contained in the fermented product and/or the culture of the bacterium. Sheath lipid.

As the additional sheath lipid, the sphingolipid itself can be used as it is, but for example, it is a phospholipid concentrate (MPL) containing sphingomyelin derived from milk. Cream whey, which is a by-product of the cream or cream or the cream oil, can also be obtained in an insoluble portion of acetone (solvent) and/or ethanol. Cream whey can also be used in the field of commercially available milk (for example, New Zealand, manufactured by Tatua Co., Ltd.). Cream whey contains more MFGM which is locally present in sphingomyelin and is suitable as a raw material.

The separation of phospholipids in which sphingolipids are locally present from the cream whey utilizes the insoluble nature of phospholipids in acetone and/or ethanol. The acetone-soluble fraction containing the neutral lipid is removed by a plurality of acetone extractions to obtain a concentrated separation of the phospholipids in acetone. The composition may be obtained by dissolving the acetone insoluble and decomposing under reduced pressure, removing the acetone, and sterilizing the concentrate, followed by freeze-drying, and then pulverizing the dried product to obtain a form derived from a cream phospholipid.

Further, for example, the total lipid is extracted from the chicken skin powder, and the dried total lipid to be dried is subjected to extraction treatment with a mixed solvent of an aliphatic hydrocarbon solvent and a water-soluble ketone solvent, and the insoluble portion mainly composed of sphingomyelin is dissolved in water and water. A method in which a mixed solvent of a ketone solvent is subjected to extraction treatment to remove a sphingomyelin which is a non-lipid component contained in a soluble portion. It is also possible to use an existing method such as a fish shellfish or an animal bird extraction method. From the viewpoint of flavor, it is preferably a sphingomyelin derived from milk.

In the composition of the present invention, the fermented lactic acid bacteria and/or the fermented product and/or culture of the bacterium of the bacterium, the solid shape yoghurt (solid shape fermented milk), the soft shape yoghurt (paste fermented milk), and the drinking yoghurt It is an excellent form of various forms such as (liquid fermented milk), and may also be an excellent grain containing cereals, fruit, vegetables, and nutrients.

The composition for oral ingestion or enteral administration of the present invention is preferably one in which the sphingolipid is highly absorbed in the living body, and more preferably the sphingomyelin is highly absorbed in the living body. In other words, the composition for oral ingestion or enteral administration according to the present invention is an oral or enteral administration composition which is preferably "sphingolipid high absorbency" and preferably "sphingomyelin high absorbability". . In addition, the "sphingolipid hyperabsorbency" or the "sphingomyelin hyperabsorbability" can be confirmed by comparison with the amount of sphingomyelin absorption in the case of the conventional eutectic or the like, for example, in the first or second embodiment described later.

The lactic acid bacteria and/or the fermented product and/or culture of the bacterium of the bacterium of the present invention for oral ingestion or enteral administration based on the high absorbency of the sheath lipid or the high absorbability of the sphingomyelin The ratio of the sphingolipid to the sphingolipid is 1 mg to 10,000 mg, more preferably 5 to 5,000 mg, more preferably 10 to 750 mg of the lactic acid bacteria and/or fermented products and/or cultures of the genus Dry weight (powder)).

Similarly, based on the high absorbency of the sheath lipid or the high absorbability of the sphingomyelin, the lactic acid bacteria and/or the fermented material of the bacterium of the bacterium of the present invention for oral or enteral administration are and/or Or the ratio of the culture to the sphingolipid is 1 to 100 g, more preferably 0.05 to 50 g, and even more preferably 0.1 to 7.5 g of the lactic acid bacteria and/or the bacterium than the sphingolipid Fermentation and/or culture (wet weight).

The oral ingestion or enteral administration composition of the present invention is preferably used for the action in the body induced by the absorption of sphingomyelin into the living body. Therefore, the oral ingestion or enteral administration composition of the present invention is preferably used in the above-mentioned living body to prevent or improve the deterioration of the skin condition, the cancer suppressing action, the skin-beautifying effect, and the development of infant brain development. The role of the function of granules, the function of mitochondrial function, the improvement of motor function, the inhibition of visceral fat accumulation, the promotion of blood lipid concentration and the prevention of infectious diseases.

The orally administered or enteral composition of the present invention is preferably used for preventing, inhibiting or ameliorating the deterioration of the skin condition. The deterioration of the skin condition here is preferably a deterioration of the skin barrier function. Moreover, the deterioration of the skin barrier function is preferably caused by ultraviolet radiation.

The composition of the present invention may be a pharmaceutical composition as a preferred embodiment.

In the present invention, the pharmaceutical composition can be used in combination to prepare an additive which is acceptable, and is prepared as an oral preparation or a parenteral preparation according to a usual method. It is preferably an oral preparation based on the aspect of simplicity. In the case of the oral preparation, it may be in the form of a liquid preparation such as a solid preparation, a solution, a suspension or an emulsion of a tablet, a powder, a fine granule, a granule, a capsule, a pill or a sustained release agent. The additives allowed for formulation are exemplified by, for example, excipients, stabilizers, preservatives, wetting agents, emulsifiers, slip agents, sweeteners, colorants, perfumes, buffers, antioxidants, pH adjusters, and the like. .

Moreover, according to the present invention, there is provided a food or drink comprising the present hair A sheath lipid absorption enhancer of the present invention, or a composition for oral ingestion or enteral administration as described above.

The composition and food or drink of the present invention can be produced by, for example, a method for producing a material component in which the absorption enhancer of the present invention or an active ingredient thereof is added to the composition and the food or beverage.

In the food or drink of the present invention, an optional component may be added as needed. The optional ingredients to be added are not particularly limited, and may be formulated with ingredients, sweeteners, sour materials, vegetables or fruit or nut juices or extracts thereof, vitamins, minerals, and amino acids. Useful nutrients such as nutrients, lactic acid bacteria, phenanthrene bacteria, propionic acid bacteria, or cultures thereof, functional sugars such as oligosaccharides, royal jelly, collagen, neuropterin, glucosamine, astaxanthin, and more Organic materials such as phenols, perfumes, pH adjusters, excipients, sour materials, coloring materials, emulsifiers, preservatives, and the like.

In the present invention, the food or drink is a pharmaceutical composition, and is not particularly limited as long as it is a form which can be orally ingested, such as a solution, a suspension, an opacifier, a powder, or a solid molded product. Specifically, for example, dairy products such as milk beverages, yogurts, lactic acid bacteria beverages, fermented milk, ice creams, milk fats, cheeses, and the like; refreshing drinks, juice drinks, vegetable drinks, soy milk drinks, coffee drinks, tea drinks, Powdered drinks such as jelly drinks, cocoa, smoothies, sports powder drinks, nutritionally-enhanced powder drinks, powder foods for beauty, soup powders, steamed breads, beverages such as concentrated drinks, alcoholic beverages, etc.; bread, pasta, Wheat flour products such as noodles, cake spreads, fried flour, bread flour, etc.; chocolate, chewing gum, glutinous rice, cakes Pastries such as dried, soft candy, snacks, Japanese cakes, jellies, puddings, etc.; seasonings such as seasonings, flavorings, and seasonings; curry, yummy noodles, soups, stews, Cooking foods for zephyr foods; processing oils and fats, creams, margarines, spreads, cannabis and other oils; fast-food foods such as freeze-dried foods; canned foods, jams. Agricultural products such as orange peel jam, pickles, boiled beans, nutritious cereals, and vegetable porridge; processed products of aquatic products; processed products of livestock; frozen foods such as pizza, stewed rice, braised, side dishes, fried foods; It is animal feed, tablets, cosmetics used in the oral cavity, etc.

According to a preferred aspect of the present invention, the food and beverage is a milk beverage (which may also include processed milk), fermented milk, a refreshing beverage, a jelly beverage, a tablet, a cosmetic powder food, a powdered beverage, a mobile food, and a liquid milk. Powder, according to better forms, food and beverage products are milk beverages, fermented milk, refreshing beverages, jelly drinks, tablets for preparing powdered milk, powder foods for cosmetic use, and according to a better form, food and beverage products are milk drinks (also included Processing milk), fermented milk.

In addition, foods and beverages also include functional foods, healthy and nutritious foods, supplements, health foods, specific health foods, functional display foods, nutritional functional foods, foods for sick people, infant formula, or pregnant women. Milk powder for women, or food-like classifications with reduced risk of disease. According to a preferred embodiment of the present invention, the food or beverage is a functional food, a healthy nutritious food, a supplement, a specific health food, a functional food, or a food exhibiting a reduced risk of disease.

Also, here, the so-called disease risk reduction is shown as having a reduction The display of food and beverage products with the possibility of low disease risk may be displayed or approved based on the specifications set by the FAO/WHO Joint Food Specification Committee (Codex Committee) or with reference to their specifications.

Therefore, the food or drink of the present invention can be provided as, for example, a food suitable for the improvement of the skin condition, a food suitable for the consumer, and a food suitable for the deterioration of the skin condition, that is, a so-called specific health food or functional food. .

In the foods and drinks and compositions of the present invention, in order to obtain a desired effect accompanying the absorption of sphingomyelin, the content of sphingomyelin in foods and drinks and compositions is desirably set within a specific range. The specific content can be related to the type, form or prevention of food or drink. It is difficult to generalize the purpose of improvement, but the composition of the present invention can be adjusted to adult (body weight: 60 kg) per day for 0.5 to 1500 mg, preferably 1 to 1000 mg, of sphingomyelin derived from milk. A good amount of 5 to 500 mg of ingestible.

The content of the sheath lipid such as sphingomyelin can be measured by a conventional method, but can be measured, for example, according to the descriptions of Examples 1 and 2 described later. For example, it can be measured using a liquid chromatograph using AQUASIL SP100 (4.6X250 mm, SENSHU Scientific Co., Ltd.) as a column.

At this time, as the mobile phase, for example, a solution obtained by mixing 0.5 mM phosphoric acid-citric acid buffer (pH: 3.0) and methanol at a ratio of 5 to 95 is preferably used. The measurement time was set to 20 minutes, the mobile phase flow rate was set to 0.6 mL/min, the column temperature was set to 40 ° C, and the absorbance was set to 205 nm for detection. As the standard substance, for example, sphingomyelin (derived from Milk, Changliang Science Co., Ltd.) can be used, and the ratio is determined by the area ratio.

According to another aspect of the present invention, the content of the active ingredient in the food or beverage and the composition may also be specified in each package form. For example, in the case of food or drink, the sphingolipid content is 5 to 1500 mg, preferably 6 to 1000 mg, more preferably. When it is contained in the range of 7 to 500 mg, and the composition, the sheath lipid content is 0.5 to 1500 mg, preferably 1 to 1000 mg, more preferably 5 to 500 mg. Moreover, the amount (content) of each package form is not limited to the intake amount of one time, and may also include the intake amount of a plurality of times or a plurality of days (for example, 30 days). For example, when the food or drink is used, the amount of sheath lipid is 5~. 45000 mg, preferably 6 to 30000 mg, more preferably 7 to 15000 mg, and the composition has a sheath lipid content of 0.5 to 45000 mg, preferably 1 to 30000 mg, more preferably 5 to 15000 mg.

In the conventional milk beverage and fermented milk, the lipid contains phospholipid at 20 mg per 1 g. However, the milk beverage and fermented milk of the present invention may contain phospholipids in an amount of 25 to 3000 mg per 1 g of the lipid, preferably 30 to 2500 mg. It is 40~2000mg, and more preferably 50~1500mg. In the conventional milk beverage and fermented milk, the lipid contains sphingomyelin at 6 mg per 1 g, but the food or drink or composition of the present invention may contain sphingomyelin at 7 to 1500 mg per 1 g of the lipid, preferably 8 to 1250 mg. It is better to use 9~1000mg, and more preferably 10~750mg. That is, in a preferred aspect of the invention, those who deliberately increase the sphingomyelin content are used.

When the milk beverage or fermented milk of the present invention contains a lipid in a usual amount (for example, 3% by weight of a lipid), the phospholipid may be contained in an amount of 1 to 300 mg/g, preferably 1.5 to 250 mg/g, more preferably 2 ~200mg / g, and more preferably 2.5 ~ 150mg / g. And the present invention When the food or drink or the composition contains the lipid in a usual amount, it may be contained in the sphingomyelin at 0.2 to 60 mg/g, preferably 0.25 to 50 mg/g, more preferably 0.3 to 40 mg/g, and even more preferably 0.35~ 30mg/g contains.

On the other hand, in the conventional milk beverage and fermented milk, the lipid contains phospholipids in an amount of 20 mg per 1 g, but the milk beverage and the fermented milk of the present invention may contain phospholipids in an amount of 25 to 3000 mg per 1 g of the lipid, preferably 30%. 2500mg, more preferably 40~2000mg, and more preferably 50~1500mg. Further, when the food or drink or the composition of the present invention contains a small amount of lipid, it may be contained in the sphingomyelin at 0.05 to 60 mg/g, preferably 0.1 to 50 mg/g, more preferably 0.15 to 40 mg/g, and further preferably 0.2~30mg/g containing.

In addition, the conventional milk beverage and fermented milk contain phospholipids in an amount of 20 mg per 1 g of the lipid, but the milk beverage and the fermented milk of the present invention may contain phospholipids in an amount of 25 to 3000 mg per 1 g of the lipid, preferably 30 to 2500 mg. It is better to use 40~2000mg, and more preferably 50~1500mg. Further, when the milk beverage, the fermented milk, the refreshing beverage, the jelly drink, the tablet, and the cosmetic powder food of the present invention contain almost no lipid (no fat), the sphingomyelin may be contained in an amount of 0.02 to 60 mg/g, preferably 0.04. ~50 mg / g, more preferably 0.06 ~ 40 mg / g, and more preferably 0.08 ~ 30 mg / g.

According to another aspect of the present invention, there is provided a method for promoting absorption of sphingolipids, which comprises simultaneously orally administering a lactic acid bacterium and/or a fermented bacterium of the genus Fischerellae to a subject desirably taking sphingolipids and a sphingolipid. Or culture. Here, it is preferred that the sheath lipid is a sphingomyelin.

According to still another aspect of the present invention, there is provided a method for promoting absorption of a neural guanamine, which comprises simultaneously orally administering a lactic acid bacterium and/or a fermented product of a bacterium of the genus And / or culture.

Moreover, it is preferable that the above method is a medical use exclusion. Further, the aforementioned object is preferably a mammal other than a human or a human.

Further, the above method may be an absorption of a sheath lipid for a subject which is preferably orally ingested for 2 days or longer, or administered to a lactic acid bacterium and/or a fermented product and/or culture of a bacterium of the genus A method for promoting absorption of a nervous guanamine for a method for promoting a method of ingesting sphingolipids.

[Examples]

Hereinafter, the present invention will be described in more detail by the following examples, but the invention is not limited thereto.

Example 1: Absorbency evaluation test of sphingomyelin which is administered simultaneously with sphingomyelin

The rats were administered only sphingomyelin derived from milk, or a granule of sphingomyelin derived from milk and a sphingomyelin derived from milk, and the amount of sphingomyelin absorbed into the lymph was evaluated.

〔experimental method〕

According to the method of Sugawara et al. (J. Lipid Res. 2010, 51, 1761-1769) Experiments were conducted. Specifically as follows.

(1-1) Administration of sphingomyelin and recovery of lymph fluid

After the rats (SD line, male, body weight: about 350 g) were domesticated for 1 week, the catheter was placed in the chest lymph and the stomach, and a buffer pump (glucose: 139 mM, sodium chloride: 85 mM) was used. The solution was administered to the stomach (flow rate: 3 mL/min) for one night (about 12 hours).

Next, the rats were divided into three groups (a, b, and c) corresponding to the respective test solutions (A), (B), and (C) described later, and the respective test solutions were administered to the stomach. A few hours ago, the lymph was recovered into EDTA-treated centrifuge tubes for 3 groups (a, b, c).

Further, using a syringe pump, each test solution (A), (B), and (C) (3 mL each) was supplied to the stomach (flow rate: 3 mL/min) in 1 minute, and then a syringe pump was used for 6 hours. The solution was administered to the stomach (flow rate: 3 mL/min).

Next, the lymph fluid was recovered to the EDTA-treated centrifuge tube for each of the three groups (a, b, c) every hour.

(1-2) Test solution

Each test solution (A), (B), and (C) was prepared as follows.

(A) mixed triglyceride: 200 mg, bovine serum albumin: 50 mg, and sodium taurocholate: 200 mg

(B) Ultrasonic in a liquid mixture of triglyceride: 195 mg, bovine serum albumin: 50 mg, and sodium taurocholate: 200 mg Sphingolipids derived from milk (SM, purity 98%, Changliang Science Co.): 5 mg emulsified.

(C) in a liquid mixture of triglyceride: 192 mg, bovine serum albumin: 50 mg, and sodium taurobate: 200 mg, supersonic-derived sphingomyelin from milk (SM, purity 98%, Changliang Science) Company): 4.75 mg emulsified. With it, prepare the powder of Yogurt (YG, fat: about 0%, Meiji Bulgarian Yogurt Fat Zero, obtained from Meiji Co., Ltd.): 250mg

(1-3) Composition of the evaluation group

The three groups (a, b, and c) corresponding to the test solutions (A), (B), and (C) are as follows, and the contents are shown in Table 1. Further, each group of rats was 5 rats.

(a) Control group: Test solution (A): 3 mL/rat (SM: 0 mg/rat) was administered intragastrically.

(b) SM group: Test solution (B): 3 mL/rat (SM: 5 mg/rat) was intragastrically administered.

(c) SM+YG group: In combination with test solution (C): 3 mL/rat (SM: 4.75 mg/rat), YG: 250 mg/rat was administered intragastrically.

(1-4) Evaluation indicators

After the test solution was administered, the amount of sphingomyelin absorption of the lymph fluid of the rat was evaluated. Specifically, a neuropterin molecule (d16:1-C16:0) and a sphingomyelin molecular species (d16:1-C16) which are not present in the lymph of the rat and are specifically present with the sphingomyelin derived from milk. The dynamics of :0 SM) are used as indicators to compare absorption differences.

(1-5) Analysis method

The extraction of lipid from the lymph fluid taken from the rat is based on the method of Folch et al. (J. Biol. Chem., 1957, 226, 497-509).

Specifically, physiological saline was added to the lymph solution: 200 μL (when the lymph was recovered at 2.5 mL/h): 800 μL, and a mixture of chloroform-methanol (2:1 (v/v)) was added: 4 mL, and shaken ( 200 rpm, 15 minutes). Next, after centrifugation (2000 rpm, 10 minutes), the lower layer was transferred to another tube, and after centrifugation and concentration, methanol: 500 μL was added to prepare a neural amine. Analytical sample. Further, the sample for analysis of sphingomyelin was prepared by diluting it by 10 times with methanol.

The standard strains used neuropterin (d18: 1-C16:0, obtained from Avanti polar lipids), sphingomyelin (d18: 1-C16:0, SM, obtained from Avanti polar lipids). These standards were used as equivalents, and LC/MS/MS (ACQUITY premier XE (manufactured by Waters)) was used to quantify neuropterin (d16:1-C16:0) and sphingomyelin (d16:1-C16:0). SM). At this time, the column used was ACQUITY UPLC BEH C18 (2 mm × 100 mm, manufactured by Waters), the mobile phase A was ammonium acetate (5 mM) / methanol (95%), and the mobile phase B was ammonium acetate (5 mM) / methanol.

Next, the mobile phase A starts from 100%. After 30 minutes, the mobile phase B becomes 100%, and the mobile phase B is kept at 100% for 2 minutes. After 3 minutes, the mobile phase A is switched to 100%. Here, the measurement time of one sample in LC/MS/MS is set to 35 minutes, the flow rate of the mobile phase is set to 0.4 mL/min, the column temperature is set to 40 ° C, and electrospray ionization is used to detect in positive mode. . As an analysis variable of LC/MS/MS, the capillary voltage was set to 3000 V, the source temperature was set to 120 ° C, the desolvation temperature was set to 400 ° C, the desolvation gas flow rate was set to 850 L / hour, and the cone gas flow rate was set to At 50 L/hour, the cone voltage was set to 40 V/hour.

〔result〕

The results are shown in Figures 1 and 2.

Figure 1 shows the shift in the amount of neuropterin molecular species (d16:1-C16:0). Here, after 4, 5, and 6 hours after oral administration of each test solution, the amount of neuropterin molecules in the SM+YG group was high as compared with the SM group.

Fig. 2 shows the transition of the amount of the sphingomyelin molecular species (d16: 1-C16: 0 SM). Here, after 3, 4, 5, and 6 hours after oral administration of each test solution, the amount of sphingomyelin molecular species was high in the SM+YG group compared with the SM group.

From these results, it was found that the simultaneous absorption of sphingomyelin and yoghurt by oral administration promoted the absorption of ceramide and also promoted the absorption of sphingomyelin.

Experimental Example 2: Absorption evaluation test of sphingomyelin which simultaneously ingested Yogurt and phospholipid concentrate (MPL) derived from milk containing high amount of sphingomyelin

Rats were orally administered with MPL only, or both were administered orally with MPL to evaluate the amount of neuropterin in the blood.

〔experimental method〕 (2-1) Oral administration and blood collection of MPL

Rats (SD line, male, body weight: about 300 g) were domesticated for 1 week. Then, the rats were fasted for 16 hours, and then divided into 2 groups, and each of the test solutions (D) and (E) shown below was orally administered, before administration, 90 minutes after the administration, and 180 minutes after the administration. After 270 minutes, 360 minutes, blood was collected from the tail vein. Next, serum is obtained according to a usual method.

(2-2) Composition of the evaluation group

(d) MPL group: Test solution (D): The amount of MPL: 540 mg (100 mg in terms of sphingomyelin) was administered per 1 kg of body weight.

(e) MPL+YG group: test solution (E): body weight per 1 kg, administered to Yogur (Meiji Bulgarian Yogurt Fat Zero, obtained from Meiji Co., Ltd.): 11.3 g and MPL: 535 mg (to total sphingomyelin) The amount is calculated as 100 mg).

(2-3) Evaluation indicators

After the test solution was orally administered, the amount of neuropterin in the serum of the rats was evaluated.

Specifically, the neuropterin molecule which is not present in the serum of the rat and specifically exists with the sphingomyelin derived from milk (d16: 1-C16:0, d16:1-C22:0, d16:1- The dynamics of C23:0, d16:1-C24:0) were used as indicators to compare the differences in serum concentrations.

(2-4) Analysis method

The extraction of serum lipids from rats is based on the method of Folch et al. (J. Biol. Chem., 1957, 226, 497-509).

Specifically, physiological saline was added to 50 μL of serum: 200 μL, and then a mixed solution of chloroform-methanol (2:1 (v/v)): 1 mL was added thereto, followed by extraction. Next, after centrifugation (2000 rpm, 10 minutes), the lower layer was transferred to another tube, and after centrifugation and concentration, methanol: 200 μL was added to prepare a sample for analysis of neural guanamine.

The standard strain used neuropterin (d18: 1-C16:0, d18:1-C22:0, d18:1-C23:0, d18:1-C24:0, obtained from Avanti polar lipids). These standards were used as equivalents, and the amount of neuropterin was quantified using LC/MS/MS (ACQUITY premier XE (manufactured by Waters)) (d16: 1-C16:0, d16:1-C22:0, d16:1) -C23:0, d16:1-C24:0). At this time, the column used was ACQUITY UPLC BEH C18 (2 mm × 100 mm, manufactured by Waters), the mobile phase A was ammonium acetate (5 mM) / methanol (95%), and the mobile phase B was ammonium acetate (5 mM) / methanol.

Next, the mobile phase A starts from 100%. After 30 minutes, the mobile phase B becomes 100%, and the mobile phase B is kept at 100% for 2 minutes. After 3 minutes, the mobile phase A is switched to 100%. Here, the measurement time of one sample in LC/MS/MS is set to 35 minutes, the flow rate of the mobile phase is set to 0.4 mL/min, the column temperature is set to 40 ° C, and electrospray ionization is used to detect in positive mode. . As an analysis variable of LC/MS/MS, the capillary voltage was set to 3000 V, the source temperature was set to 120 ° C, the desolvation temperature was set to 400 ° C, the desolvation gas flow rate was set to 850 L / hour, and the cone gas flow rate was set to 50 L / hour. The cone voltage was set to 40 V/hour.

〔result〕

The results are shown in Figures 3 and 4.

Figure 3 shows the change in the amount of serum neuropterin molecular species (d16:1-C16:0, d16:1-C22:0, d16:1-C23:0, d16:1-C24:0) Chemical. The neuropterin molecular species (d16:1-C16:0) is 90 minutes after 180 minutes after administration of the test solution, and the neuropterin molecular species (d16:1-C22:0, d16:1-C23:0) are After 90, 180, and 270 minutes after administration of the test solution, the neuropterin molecular species (d16:1-C24:0) was compared with the MLP group after 90, 180, 270, and 360 minutes after administration of the test solution, MPL+YG. In the group, it is a meaningful high value.

Figure 4 is a graph showing the area under the time curve of the amount of neuropterin molecules in serum. The area under the time curve of each neural amine molecule species is a significant high value in the MPL+YG group compared to the MPL population.

It can be seen that the absorption of sphingomyelin is promoted by simultaneously ingesting a phospholipid concentrate derived from milk containing high amounts of sphingomyelin and yoghurt.

Example 3: Effect of eugle and sphingolipid on the deterioration of skin barrier function under ultraviolet irradiation

For nude mice with deteriorating skin barrier function due to ultraviolet radiation, oral administration of sphingomyelin or sphingomyelin and Yogurt for 3 days was evaluated for skin barrier function (striatum water content, transepidermal water evaporation (TEWL)) The impact.

A sphingomyelin derived from milk (SM, purity 98%, Changliang Science Co., Ltd.) was used as the sheath lipid system.

〔experimental method〕 (3-1) Deterioration of skin barrier function induced by ultraviolet radiation

The nude mice (Hos: HR-1, female, 4 weeks old, Hoshino test animal breeding house) were domesticated for 1 week, and irradiated with ultraviolet rays at 20 mJ/cm ² (UV-B (GL20SE, Sankyo Electric Co., Ltd.) the company)).

(3-2) Composition of the evaluation group

A test system in which the skin barrier function is deteriorated is used to evaluate the effect of sphingomyelin or sphingomyelin and yoghurt administration on the skin condition. The test system of each group was set to 8. The relationship between the composition of the animal experiment only (the composition of the evaluation group) and the sphingomyelin and the content of the yoghurt is shown below.

Control group (Control group): a group of normal feeds

SM group: Oral administration of sphingomyelin 10 mg/kg/day

SM+YG group: sphingomyelin and yoghurt group administered orally at 10 mg/kg/day and 11.3 g/kg/day, respectively

(However, the SM group and the SM+YG group are administered orally to collagen in a ratio of 1000 mg/kg/day in addition to sphingomyelin or yoghurt).

(3-3) Evaluation test method

The stratum corneum moisture content and TEWL were measured for each test group, thereby evaluating the barrier function of the skin.

(3-3-1) Cuticle water content

The water content of the stratum corneum is 5 times per skin using a skin moisture meter (Corneometer, Courage and Khazaka Electronic GmbH). The measurement was carried out. Among them, the average of the three measured values after removing the maximum value and the minimum value is used as the water content of the stratum corneum.

(3-3-2) Transepidermal water evaporation (TEWL)

The transepidermal water evaporation (TEWL) was measured by a skin moisture loss meter (Tewemeter MPA580, Courage and Khazaka Electronic GmbH) and probed at 29 ° C for 20 seconds. With respect to the measurement results thus obtained, the average of three times was used as the amount of transepidermal water evaporation.

〔Evaluation results〕 (the stratum corneum water content)

The result is shown in Figure 5.

In Fig. 5, the stratum corneum water content of the SM group and the SM+YG group is high compared to the stratum corneum water content of the control group. Further, the SM+YG group has a higher value than the SM group. Therefore, it is considered that the SM+YG group is more capable of suppressing (improving) the deterioration of the skin barrier function than the SM group.

(Transdermal water evaporation (TEWL))

The result is shown in Figure 6.

In Fig. 6, the TEWL of the SM group is lower than the TEWL of the control group. Furthermore, the SM+YG group has a lower value than the SM group. Therefore, it is considered that the SM+YG group is more capable of suppressing (improving) the deterioration of the skin barrier function than the SM group.

It is taught that by the oral administration of the sheath lipid and the yogurt (fermented milk), the deterioration of the ultraviolet-based skin barrier function can be further suppressed (improved). Furthermore, it is suggested that the sphingolipid and the yogurt (fermented milk) are continuously ingested for three days or more, and it is easy to suppress (improve) the deterioration of the skin barrier function.

Example 4: Absorption evaluation test of sphingomyelin which was taken up simultaneously with unfermented milk and MPL

The amount of neurosteroids in the blood was evaluated separately for the case where the rats were orally administered with MPL, the conditions of oral administration of yoghurt and MPL, and the simultaneous administration of unfermented milk and MPL.

〔experimental method〕 (4-1)

Rats (SD line, male, body weight: about 270 g) were domesticated for 1 week. Subsequently, the rats were fasted for 16 hours, and then divided into three groups, and each of the test solutions (F), (G) and (H) shown below was orally administered. Next, blood was collected from the tail vein before the administration, 90 minutes after the administration, 180 minutes later, 270 minutes later, and 360 minutes later, and serum was obtained according to a usual method.

(4-2) Composition of the evaluation group

(f) MPL group: Test solution (F): The amount of MPL: 540 mg (100 mg in terms of sphingomyelin) was administered per 1 kg of body weight.

(g) MPL+YG group: test solution (G): body weight per 1 kg, cast Yuge (Meiji Bulgarian Yogurt Fat Zero, obtained from Meiji Co., Ltd.): 11.3 g and MPL: 535 mg (100 mg based on the total amount of sphingomyelin).

(h) MPL+ unfermented milk group: test solution (H): body weight per 1 kg, and put skim milk powder (Meiji skim milk powder, obtained from Meiji Co., Ltd.): 1.3 g and MPL: 537 mg (based on the total amount of sphingomyelin) The amount of 100 mg).

(4-3) Evaluation indicators

After the test solution was orally administered, the amount of neuropterin in the serum of the rats was evaluated.

Specifically, a neuropterin molecular species (d16: 1-C16:0, d16:1-C22:0, d16:1-C23:0, d16:1-C24:0) was used as an index.

〔result〕

The result is shown in Figure 7.

Figure 7 shows the area under the time curve of the amount of neuropterin molecules in serum. The molecular area under the time curve of any of the neuropterin molecular species is a significant high value in the order of the MPL group, the MPL+unfermented milk group, and the MPL+YG group compared with the MPL group.

It can be seen that the simultaneous absorption of the phospholipid concentrate derived from milk and the unfermented milk containing a high amount of sphingomyelin can promote the absorption of sphingomyelin by simultaneous oral administration of milk derived from high-strength sphingomyelin. The phospholipid concentrate and the yoghurt can further promote the absorption of sphingomyelin.

Example 5: Absorption evaluation test of sphingomyelin which is simultaneously taken up by yoghurt and MPL

In view of the case where only MPL is administered orally to a rat, and the case where the yoghurt and the MPL are administered orally, the yoghurt is divided into the yam and the MPL, and the yoghurt is simultaneously administered orally. In the case of MPL, the amount of neuropterin in the blood was evaluated separately.

〔experimental method〕 (5-1) Modulation method of Uyghur division

Yogurt (Meiji Bulgarian Yogurt Fat Zero, obtained from Meiji Co., Ltd.) was centrifuged at 6000 rpm for 10 minutes to obtain a Yoko Division Seiko and Yogurt Sediment.

(5-2)

Rats (SD line, male, body weight: about 270 g) were domesticated for 1 week. Subsequently, the rats were fasted for 16 hours, and then divided into three groups, and the test solutions (I), (J), and (K) and (L) shown below were orally administered. Next, blood was collected from the tail vein at 90 hours, 180 minutes, 270 minutes, and 360 minutes after the administration, and serum was obtained according to a usual method.

(5-3) Composition of the evaluation group

(i) MPL group: test solution (I): body weight per 1 kg, administered MPL: 540 mg (100 mg in terms of sphingomyelin).

(j) MPL+YG group: test solution (J): per kg of body weight, administered to Yogur (Meiji Bulgarian Yogurt Fat Zero, obtained from Meiji Co., Ltd.): 11.3g and MPL: 535mg (to the total amount of sphingomyelin The amount is calculated as 100 mg).

(k) MPL+YG Shangcheng group: test solution (J): For every 1 kg of body weight, the amount of yoghurt extract: 743 mg and MPL: 539 mg (100 mg based on the total amount of sphingomyelin) was administered.

(1) MPL+YG Precipitate: Test solution (K): For every 1 kg of body weight, a dose of 455 mg and MPL: 536 mg (100 mg based on the total amount of sphingomyelin) was administered.

(5-4) Evaluation indicators

After the test solution was orally administered, the amount of neuropterin in the serum of the rats was evaluated.

Specifically, a neuropterin molecular species (d16: 1-C16:0, d16:1-C22:0, d16:1-C23:0, d16:1-C24:0) was used as an index.

〔result〕

The result is shown in Figure 8.

Figure 8 shows the area under the time curve of the amount of neuropterin molecules in serum. The molecular area under the time curve of any of the neuropterin species, compared with the MPL group, the MPL+YG group and the MPL+YG group, became significant high values, but there was no difference between the MPL group and the MPL+YG precipitation group. See you there Poor meaning.

It can be seen that the absorption of sphingomyelin is promoted by simultaneous oral administration of a high amount of a phospholipid concentrate derived from milk which is derived from sphingomyelin. These results are considered to indicate that the yoghurt contains a component that promotes the absorption of sphingomyelin.

Example 6: Absorption evaluation of sphingomyelin which simultaneously ingested lactic acid and MPL

The amount of neurosteroids in the blood was evaluated separately for the case where the rats were administered MPL only by oral administration, the conditions of oral administration of yoghurt and MPL, and the simultaneous administration of lactic acid and MPL.

〔experimental method〕 (6-1)

Rats (SD line, male, body weight: about 270 g) were domesticated for 1 week. Then, the rats were fasted for 16 hours, and then divided into three groups, and the test solutions (L), (M) and (N) shown below were orally administered. Next, blood was collected from the tail vein at 90 minutes, 180 minutes, 270 minutes, and 360 minutes after the administration, and serum was obtained according to a usual method.

(6-2) Composition of the evaluation group

(1) MPL group: Test solution (L): The amount of MPL: 540 mg (100 mg in terms of sphingomyelin) was administered per 1 kg of body weight.

(m) MPL+YG group: test solution (M): body weight per 1 kg, Invested in Yogurt (Meiji Bulgarian Yogurt Fat Zero, obtained from Meiji Co., Ltd.): 11.3 g and MPL: 535 mg (100 mg based on the total amount of sphingomyelin).

(n) MPL + lactic acid group: test solution (N): body weight per 1 kg, lactic acid (obtained from Wako Pure Chemical Industries Co., Ltd.): 109 mg (the amount of lactic acid in Yogurt is equal to pH) and MPL: 540 mg (in terms of The total amount of sphingomyelin is 100 mg).

(6-3) Evaluation indicators

After the test solution was orally administered, the amount of neuropterin in the serum of the rats was evaluated.

Specifically, a neuropterin molecular species (d16: 1-C16:0, d16:1-C22:0, d16:1-C23:0, d16:1-C24:0) was used as an index.

〔result〕

The result is shown in Figure 9.

Figure 9 shows the area under the time curve of the amount of neuropterin molecules in serum. Compared with the MPL group, the MPL+YG group became a significant high value for any of the neuropterin molecular species, but there was no significant difference between the MPL group and the MPL+lactic acid group.

From these results, it is considered that lactic acid in the yoghurt is not a component that promotes the absorption of sphingomyelin.

Example 7: simultaneous intake of whey protein value and sphingomyelin absorption of MPL Evaluation test

The amount of neurosteroids in the blood was evaluated separately for the case where the rats were orally administered with MPL, the conditions of oral administration of yoghurt and MPL, and the simultaneous administration of whey protein and MPL.

〔experimental method〕 (7-1)

Rats (SD line, male, body weight: about 270 g) were domesticated for 1 week. Subsequently, the rats were fasted for 16 hours, and then divided into three groups, and the test solutions (O), (P) and (Q) shown below were orally administered. Next, blood was collected from the tail vein at 90 minutes, 180 minutes, 270 minutes, and 360 minutes after the administration, and serum was obtained according to a usual method.

(7-2) Composition of the evaluation group

(o) MPL group: test solution (O): body weight per 1 kg, administration of MPL: 540 mg (100 mg in terms of sphingomyelin).

(p) MPL+YG group: test solution (P): body weight per 1 kg, administered to Yogur (Meiji Bulgarian Yogurt Fat Zero, obtained from Meiji Co., Ltd.): 11.3 g and MPL: 535 mg (to total sphingomyelin) The amount is calculated as 100 mg).

(q) MPL + whey protein group: test solution (Q): whey protein (ARASEN 8899, obtained from FONTERRA) per ml of body weight: 109 mg (equal to the amount of whey protein in Yogurt) and MPL: 540 mg (100 mg based on the total amount of sphingomyelin).

(7-3) Evaluation index

After the test solution was orally administered, the amount of neuropterin in the serum of the rats was evaluated.

Specifically, a neuropterin molecular species (d16: 1-C16:0, d16:1-C22:0, d16:1-C23:0, d16:1-C24:0) was used as an index.

〔result〕

The result is shown in Figure 10.

Figure 10 shows the area under the time curve of the amount of neuropterin molecules in serum. The molecular area under the time curve, the MPL+YG group became a significant high value compared to the MPL group, but there was no significant difference between the MPL group and the MPL+whey protein group.

From these results, it is considered that the whey protein in the yoghurt is not a component that promotes the absorption of sphingomyelin.

Example 8: Evaluation test of sphingomyelin absorption of polysaccharides and MPL simultaneously

The amount of neurosteroids in the blood was evaluated separately for the case where the rats were administered MPL only by oral administration, the conditions of oral administration of yoghurt and MPL, and the simultaneous administration of polysaccharides and MPL.

〔experimental method〕 (8-1) Refinement of polysaccharides

The purification of polysaccharides is based on the method of Cerning et al. (J. Dairy Sci., 1992, 75, 692-699). Yogurt Seiki is treated with protease (Roche) to hydrolyze proteins. A three-fold amount of ethanol was added, and the mixture was frozen for one night, and a polysaccharide-containing precipitate was obtained by centrifugation. The precipitate was subjected to an ultrafiltration membrane (Merck Millipore, Centriprep Ultracel YM-3) to remove protein hydrolyzate and to refine the polysaccharide.

(8-2)

Rats (SD line, male, body weight: about 270 g) were domesticated for 1 week. Subsequently, the rats were fasted for 16 hours, and then divided into three groups, and the test solutions (R), (S) and (T) shown below were orally administered. Next, blood was collected from the tail vein at 90 minutes, 180 minutes, 270 minutes, and 360 minutes after the administration, and serum was obtained according to a usual method.

(8-3) Composition of the evaluation group

(r) MPL group: test solution (R): body weight per 1 kg, administration of MPL: 540 mg (100 mg in terms of sphingomyelin).

(s) MPL+YG group: test solution (S): body weight per 1kg, administered to Yogur (Meiji Bulgarian Yogurt Fat Zero, obtained from Meiji Co., Ltd.): 11.3g and MPL: 535mg (to the total amount of sphingomyelin The amount is calculated as 100 mg).

(t) MPL+ polysaccharide group: test solution (T): body weight per 1 kg, The polysaccharide was administered in an amount of 52.5 mg (equivalent to the polysaccharide in Yogurt) and MPL: 540 mg (100 mg in terms of sphingomyelin).

(8-4) Evaluation index

After the test solution was orally administered, the amount of neuropterin in the serum of the rats was evaluated.

Specifically, a neuropterin molecular species (d16: 1-C16:0, d16:1-C22:0, d16:1-C23:0, d16:1-C24:0) was used as an index.

〔result〕

The result is shown in FIG.

Figure 11 shows the area under the time curve of the amount of neuropterin molecules in serum. The molecular area under the time curve of any of the neuropterin species, compared with the MPL group, the MPL+YG group and the MPL+ polysaccharide group are of high significance.

The sphingomyelin absorption can be promoted by simultaneous oral administration of a phospholipid concentrate derived from milk and a polysaccharide derived from yoghurt containing a high amount of sphingomyelin, and the polysaccharide in yoghurt is considered to be a component for promoting sphingomyelin absorption. one.

Example 9: Evaluation test for simultaneous absorption of sphingomyelin absorption of yoghurt and MPL prepared by lactic acid bacteria and/or Bifidobacterium

The amount of neurosteroid in blood was evaluated separately for the case where the rats were orally administered with MPL only by oral administration of yoke and MPL prepared by lactic acid bacteria and/or Bifidobacterium.

(9-1)

Rats (SD line, male, body weight: about 270 g) were domesticated for 1 week. Then, the rats were fasted for 16 hours, and then divided into three groups, and the test solutions (U), (V), (W), (X), and (Y) shown below were orally administered. Next, blood was collected from the tail vein at 90 minutes, 180 minutes, 270 minutes, and 360 minutes before the administration, and serum was obtained according to a usual method.

(9-2) Composition of the evaluation group

(u) MPL group: test solution (U): body weight per 1 kg, administration of MPL: 540 mg (100 mg in terms of sphingomyelin).

(v) MPL+YG(1) group: test solution (V): per kg of body weight, administered to Yogurt (1) (modulated by lactic acid bacteria Lactobacillus brevis and Streptococcus thermophilus, Meiji Probio LG21 fat zero, Obtained from Meiji Co., Ltd.: 11.3 g and MPL: 535 mg (100 mg based on the total amount of sphingomyelin).

(w) MPL+YG(2) group: test solution (W): body weight per 1kg, administered to Yogurt (2) (modulated by lactic acid bacteria Lactobacillus bulgaricus and Streptococcus thermophilus, Meiji Probio Yogurt R-1 fat zero , obtained from Meiji Co., Ltd.): 11.3 g and MPL: 535 mg (100 mg based on the total amount of sphingomyelin).

(x) MPL+YG(3) group: test solution (W): per kg of body weight, administered to Yogurt (3) (longed by lactic acid bacteria Lactobacillus brevis and Pichia Bifidobacterium bacterium preparation, NATURE hui megumi fat 0 (zero), obtained from MEGAMILK SNOW Co., Ltd.): 11.3 g and MPL: 535 mg (100 mg based on the total amount of sphingomyelin).

(y) MPL+YG (4) group: test solution (Y): body weight per 1 kg, administered to Yogurt (4) (Bifidus BB536 original Yogurt fat zero prepared by Bifidobacterium longum Bifidobacterium, from Morinaga Dairy Co., Ltd. obtained: 11.3 g and MPL: 535 mg (100 mg based on the total amount of sphingomyelin).

(9-3) Evaluation indicators

After the test solution was orally administered, the amount of neuropterin in the serum of the rats was evaluated.

Specifically, a neuropterin molecular species (d16: 1-C16:0, d16:1-C22:0, d16:1-C23:0, d16:1-C24:0) was used as an index.

〔result〕

The result is shown in FIG.

Figure 12 shows the area under the time curve of the amount of neuropterin molecules in serum. Molecular species under the time curve, compared with the MPL group, MPL+YG(1) group, MPL+YG(2) group, MPL+YG(3) group, MPL+YG(4) group For meaningful high values.

It is believed that the simultaneous administration of a phospholipid concentrate derived from milk containing a high amount of sphingomyelin and various eutectic granules prepared by lactic acid bacteria and/or phenanthrene bacteria can promote the absorption of sphingomyelin.

Example 10: Absorption evaluation test of saccharide neural guanamine which simultaneously ingested yoghurt and glucosylceramide

The amount of neurosteroids in the blood was evaluated separately for the case where the rats were orally administered with glucosylceramide (GC) and the oral administration of eugle and glucosamine.

〔experimental method〕 (10-1)

Rats (SD line, male, body weight: about 270 g) were domesticated for 1 week. After the rats were fasted for 16 hours, they were divided into three groups and orally administered to the test solutions (Y) and (Z) shown below, before the administration, after 90 minutes, and after 180 minutes. Blood was collected from the tail vein at 270 minutes and after 360 minutes, and serum was obtained according to a usual method.

(10-2) Composition of the evaluation group

(y) GC group: Test solution (Y): Body weight per 1 kg, administration of GC: 1613 mg (100 mg in terms of glycosylamine, NIPPON CERAMIDE RPS, obtained from Japanese milling).

(z) GC+YG group: test solution (Z): body weight per 1 kg, administered to Yogur (Meiji Bulgarian Yogurt Fat Zero, obtained from Meiji Co., Ltd.): 11.3 g and GC: 1613 mg.

(10-3) Evaluation indicators

After the test solution was ingested, the amount of neuropterin in the serum of the rats was evaluated.

Specifically, by the report of Sugawara et al. (J. Lipid Res., 2010, 51, 1761-1769), a known increase in serum neuropterin molecular species after administration of glucosylceramide (d18:2- C16:0, d18:2-C23:0) as an indicator.

〔result〕

The result is shown in FIG.

Figure 13 shows the area under the time curve of the amount of neuropterin molecules in serum. The molecular area under the time curve of any of the neuropterin species, the GC+YG group is a significant high value compared to the GC group.

It can be seen that the absorption of glycosylamine can be promoted by simultaneous oral ingestion of glycosylamine and yoghurt.

Claims (19)

A sheath lipid absorption enhancer comprising a lactic acid bacterium and/or a fermented product and/or culture of a bacterium of the bacterium, as an active ingredient. The sheath lipid absorption enhancer of claim 1, wherein the sphingolipid is sphingomyelin and promotes absorption of sphingomyelin into the living body. The sheath lipid absorption enhancer of claim 2, which promotes absorption of the sphingomyelin derived from milk into the living body. The sphingolipid absorption enhancer according to any one of claims 1 to 3, wherein the sphingolipid is a neurolamine, a glucosylceramide, or a galactose neural amide. The sheath lipid absorption enhancer according to any one of claims 1 to 4, wherein the lactic acid bacteria and/or the fermented product and/or the culture of the bacterium lactic acid bacteria and/or the milk fermented product of the lactic acid bacteria and/or the bacterium Milk culture. A sheath lipid absorption enhancer is a polysaccharide as an active ingredient. A composition for oral ingestion or enteral administration comprising the sheath lipid absorption enhancer according to any one of claims 1 to 6 and a sheath lipid. A composition for oral ingestion or enteral administration comprising a lactic acid bacterium and/or a fermented product and/or a culture of the bacterium, and an additional sheath lipid. The composition for oral ingestion or enteral administration according to claim 7 or 8, wherein the ratio of the lactic acid bacteria and/or the fermentation product and/or the culture of the bacterium of the bacterium to the sphingolipid is relative to the sphingolipid 1 mg, containing 1 to 10000 mg of lactic acid bacteria and/or fermented products and/or cultures of P. vivi (dry weight) (powder)). The composition for oral ingestion or enteral administration according to claim 7 or 8, wherein the ratio of the lactic acid bacteria and/or the fermentation product and/or the culture of the bacterium of the bacterium to the sphingolipid is relative to the sphingolipid 1 mg contains 0.01 to 100 g of lactic acid bacteria and/or fermented products and/or cultures (wet weight) of Pf. The composition for oral ingestion or enteral administration according to any one of claims 7 to 10, wherein the sphingolipid sphingomyelin. The composition for oral ingestion or enteral administration according to any one of claims 7 to 11, which is for use in a living body induced by absorption of sphingomyelin into a living body. The composition for oral administration or enteral administration according to claim 12, wherein the induced action in the living body is caused by preventing or improving the deterioration of the skin condition, the cancer suppressing action, the skin-beautifying effect, the promoting effect of the brain development of the infant, and the granule The line body function can improve the action, the improvement of the motor function, the inhibition of the accumulation of visceral fat, the promotion of the blood lipid concentration increase, and the prevention of the infection. The composition for oral ingestion or enteral administration according to any one of claims 7 to 11, which is for the prevention, suppression or improvement of deterioration of the skin condition. The composition for oral ingestion or enteral administration according to claim 14, wherein the deterioration of the skin condition is deterioration of the skin barrier function. A food or drink comprising the sheath lipid absorption enhancer according to any one of claims 1 to 6, or the composition according to any one of claims 7 to 15. Things. The food or beverage according to claim 16, which is a functional food, a healthy nutritious food, a supplement, a specific health food, a functional food, or a food with a reduced risk of disease. A method for promoting absorption of a sheath lipid, which comprises simultaneously orally administering a lactic acid bacterium and/or a fermented product and/or culture of a bacterium of the genus Helicobacter pylori to a subject desirably taking sphingolipids and a sphingolipid. An absorption promoting method according to claim 18, wherein the sphingolipid sphingomyelin.